![MiNK Therapeutics Inc](/common/images/company/N_INKT.png)
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses. MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant...
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 4.24 | 61.0071942446 | 6.95 | 13.79 | 6.92 | 144998 | 11.09132651 | CS |
4 | 3.641 | 48.2315538482 | 7.549 | 13.79 | 4.5601 | 147050 | 9.03573779 | CS |
12 | 3.411 | 43.8488237563 | 7.779 | 13.79 | 4.5601 | 133368 | 8.48661904 | CS |
26 | 2.89 | 34.8192771084 | 8.3 | 13.79 | 4.5601 | 77508 | 8.21611584 | CS |
52 | 1.69 | 17.7894736842 | 9.5 | 19 | 4.5601 | 101991 | 9.6328709 | CS |
156 | -20.81 | -65.03125 | 32 | 43.2 | 4.5601 | 110513 | 20.03849099 | CS |
260 | -109.21 | -90.7059800664 | 120.4 | 221.55 | 4.5601 | 110208 | 26.08981492 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales